Chemopreventive Efficacy of Sulindac Sulfone as a Selective Apoptotic Antineoplastic Drug in Human Head and Neck Squamous Cell Carcinoma Cell Lines: A Systematic Review

• Published in: Curēus (Palo Alto, CA) Vol. 16; no. 1; p. e51692
• Main Authors: Karuppiah, Sr, Nivethitha, B, Sivapathasundharam, Chockalingam, Rajeswari M, Bhupathy, Prem Karthick, Kalaimani, Gnanambigai, Ramamurthi, Raghini
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 05.01.2024; Cureus
• Subjects: Apoptosis; Cancer therapies; Cell cycle; Cell growth; Chemotherapy; Dentistry; Drug dosages; Enzymes; Esophagus; Head & neck cancer; Kinases; Oncology; Oral cancer; Oral Medicine; Prostate; Squamous cell carcinoma; Systematic review; Thyroid cancer; anti-inflammatory; sulindac sulfone; cell lines; anti-neoplasm; oral cancer
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.51692

Sulindac sulfone, an active metabolite of sulindac, a non-steroidal anti-inflammatory drug, has good anti-inflammatory potential. The antineoplastic effect of sulindac sulfone is mediated through a cyclooxygenase inhibitory mechanism, followed by apoptosis and inhibition of cell proliferation. Mounting studies have explored the anti-neoplastic effect of sulindac sulfone in various types of cancers in a dose-dependent manner. In this backdrop, we have conducted a systematic review to evaluate the efficacy and dose of sulindac sulfone as an anti-neoplastic agent in human head and neck squamous cell carcinoma cell lines (HNSCCs). In this study, we used a systematic literature review approach, and articles were searched in PubMed, and Medline with the keywords "sulindac sulfone," "anti-neoplastic activity," "chemopreventive," and "head and neck squamous cell carcinoma". A hand-search of journals was also performed. Articles were reviewed and analyzed. The analysis reveals that, based on the in vitro studies on various tumor models, the optimum concentration of sulindac sulfone which elicits anti-neoplastic effects is 200-800 µM. The anti-neoplastic effect is mediated through inhibition of cell proliferation and apoptosis. The results of our systematic review show that the anti-neoplastic activity of pharmacologic Sulindac sulfone is part of its dose-dependent activity, which can be safely employed in the therapy for human HNSCCs and would be responsible for a beneficial outcome of the treatment.